Unlock the potential of high-purity methylcellulose in biotech. Join our upcoming webinar to explore how METHONOVA™ enhances ...

AI transforms formulation, bioanalysis, and manufacturing; accelerated FDA reviews demand parallel development readiness; new nasal spray enhances patient drug access. In this PharmTech video feature, ...

Gain leadership and innovation insights from CEO of the Year finalist at 2025 CPHI Pharma Awards, Mahler Hanns-Christian, who ...

The CNPV pilot program significantly reduces review times, but may challenge safety standards and resource allocation.

FDA will convene a one-day, in-person and virtual public workshop, “Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine ,” on Tuesday, Dec. 16, 2025 (1). The workshop is ...

Please check back later for more content.

This session will explore best practices for sourcing and managing comparator products in clinical trials. It is designed to ...

AI and ML predict solubilization technologies, optimizing drug-excipient interactions and reducing trial-and-error in formulation development. Digital twins, trained ...

The CNPV pilot program reduces review times from 10-12 months to 1-2 months, benefiting generics and biosimilars. Companies must align market access, manufacturing, and post-approval readiness with ...

Andy Studna is an assistant editor for Pharmaceutical Executive and Applied Clinical Trials. He can be reached at [email protected].